CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-13 | BVF PARTNERS L P/IL 10% owner | Purchase | +38,558 | $9.14 | $352K | 2,691,799 |
| 2022-05-13 | BVF PARTNERS L P/IL 10% owner | Purchase | +17,744 | $9.14 | $162K | 319,415 |
| 2022-05-12 | F2 Vision SCS 10% owner | Sale | −264,072 | $9.25 | $2.4M | 1,460,539 |
| 2022-05-12 | BVF PARTNERS L P/IL 10% owner | Purchase | +542,999 | $9.06 | $4.9M | 3,599,615 |
| 2022-05-12 | BVF PARTNERS L P/IL 10% owner | Purchase | +457,001 | $9.06 | $4.1M | 2,653,241 |
| 2022-04-01 | BVF PARTNERS L P/IL 10% owner | Purchase | +266,598 | $10.75 | $2.9M | 3,056,616 |
| 2022-04-01 | BVF PARTNERS L P/IL 10% owner | Purchase | +9,402 | $10.75 | $101K | 2,196,240 |
| 2022-03-05 | AHMED NADIM President and CEO | Grant or award · Performance Stock Unit | +215,000 | 215,000 | ||
| 2022-03-01 | Martin Anne-Marie Director | Grant or award · Stock Option (Right to Buy) | +36,880 | 36,880 | ||
| 2022-02-28 | Jones Jeffrey Alan Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +215,000 | 215,000 | ||
| 2022-02-11 | Michaelson Jennifer Chief Development Officer | Grant or award | +28,500 | 51,411 | ||
| 2022-02-11 | Michaelson Jennifer Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +57,000 | 57,000 | ||
| 2022-02-11 | Keane Raymond T Chief Legal Officer | Grant or award | +22,500 | 24,124 | ||
| 2022-02-11 | Keane Raymond T Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2022-02-11 | Baeuerle Patrick See Remarks | Grant or award | +37,500 | 37,500 | ||
| 2022-02-11 | Baeuerle Patrick See Remarks | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2022-02-11 | Zawel Leigh See Remarks | Grant or award | +32,500 | 69,785 | ||
| 2022-02-11 | Zawel Leigh See Remarks | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2022-02-11 | Savill Corrine Acting Chief Business Officer | Grant or award | +16,500 | 209,615 | ||
| 2022-02-11 | Savill Corrine Acting Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +33,000 | 33,000 |
Page 14 of 23 · 446 trades